Nicotinamide: a novel treatment for age-related macular degeneration? | Zendy

Peter D. Westenskow | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nicotinamide: a novel treatment for age-related macular degeneration?

Author(s) -

Peter D. Westenskow

Publication year - 2017

Publication title -

stem cell investigation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.884

H-Index - 18

eISSN - 2313-0792

pISSN - 2306-9759

DOI - 10.21037/sci.2017.10.01

Subject(s) - macular degeneration , medicine , nicotinamide , degeneration (medical) , retinal degeneration , ophthalmology , biology , retinal , biochemistry , enzyme

Saini et al . recently reported in Cell Stem Cell that nicotinamide can suppress the expression of a broad set of genes in induced pluripotent stem cell-derived retinal pigment epithelium (iPS-RPE) cells that may contribute to age-related macular degeneration (AMD) (1). There are ample reasons to be excited about their findings, and many opportunities for future work. In this commentary, I will begin by providing background about the etiology of AMD before outlining some of the challenges of studying AMD using iPS-RPE. With that context in place, I will describe which elements of the Saini et al . study I find most exciting, and discuss potential future directions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research